Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech ...

The initial implementation phase of myUABResearch, the university’s new electronic research administration system, is on ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 12 Small Cap Stocks with High Upside Potential. On June 4, the company ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

Bids for Blackstone’s clinical trials business CMAX are believed to be due in coming days and so far Australian private ...